Erlotinib in first-line therapy for non-small cell lung cancer: A prospective phase II study

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3457-3462

  Choi, Dae Ro ^a   Lee, Dae Ho ^a   Choi, Chang Min ^a   Kim, Sang We ^a   Suh, Cheolwon ^a   Lee, Jung Shin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemo naive; EGFR mutation; Erlotinib; Non small cell lung cancer; Platinum doublet

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASIAN; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; EXPLORATORY RESEARCH; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUTATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SIDE EFFECT; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; WILD TYPE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 80054757868     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Shepherd FA, Rodrigues Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongaprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P and Seymour L: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353(2): 123-132, 2005. (Pubitemid 41058344)
2. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH and Miller VA: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25): 5892-5899, 2005.
3. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM and Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12): 1545-1552, 2007. (Pubitemid 46733081)
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36): 13306-13311, 2004. (Pubitemid 39209661)
5. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK and Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11(8): 3032-3037, 2005.
6. Lee DH, Han JY, Kim HT and Lee JS: Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer 53(3): 339-345, 2006. (Pubitemid 44209280)
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10): 947-957, 2009.
8. Lee JS, Park K, Kim SW, Lee DH, Kim HT, Han JY, Yun T, Ahn MJ, Ahn JS, Suh C, Lee JS, Han JH, Yu SY, Lee JW and Jo SJ: A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Presented at 13th World Conference on Lung Cancer, San Francisco, CA. J Thoracic Oncol 4(Suppl 1): S283 Abstract PRS 4, 2009.
9. Thatcher N, Chang A, Parikh P, Rodrigues Pereia J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496): 1527-1537, 2004. (Pubitemid 41540110)
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-206, 2000.
11. Lee DH, Kim SW, Suh C, Han YH and Lee JS: Phase II study of erlotinib for chemotherapy-na'ive patients with advanced or metastatic non-small-cell lung cancer patients who are ineligible for platinum doublets. Cancer Chemother Pharmacol 67(1): 35-39, 2011.
12. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12): 2354-2362, 2000. (Pubitemid 30415821)
13. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9): 1589-1597, 2004. (Pubitemid 41079796)
14. Soda M, Choi YL, Enomoto M, Takada S, Yamahita Y, Ihikawa S Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153): 561-566, 2007. (Pubitemid 47206930)
15. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ and Iafrate AJ: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26): 4247-4253, 2009.
16. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW and Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18): 1693-1703, 2010.